BioSeeker Group AB Research Reports

Title	Published	Price
Bladder Cancer Drug Pipeline Update 2009 By: BioSeeker Group AB Executive Summary According to the American Cancer Society, bladder cancer is the 6th most common cancer in the U.S. Bladder cancer occurs among both men and women. When found and treated early, the 5 \| more...	1/20/2009	$1,399.00
Melanoma Drug Pipeline Update 2009 By: BioSeeker Group AB Executive Summary Melanoma comprises just 5% of all skin cancers but it is the most deadly. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival \| more...	1/20/2009	$2,099.00
Colorectal Cancer Drug Pipeline Update 2009 By: BioSeeker Group AB Executive Summary Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of Avastin and Erbitux heralded a \| more...	1/20/2009	$2,099.00
Protein Kinase Inhibitors in Oncology: Drug Pipeline Update 2009 By: BioSeeker Group AB Executive Summary Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the biotechnology industry to deliver on the promise of targeted cancer drugs. However, these three successful drugs are just the top \| more...	1/20/2009	$2,099.00
Lung Cancer Drug Pipeline Update 2009 By: BioSeeker Group AB Executive Summary Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) comprises over 95% of all lung cancers. High unmet needs still persist for this tumor type and despite two decades of \| more...	1/20/2009	$2,099.00
Lymphoma Drug Pipeline Update 2009 By: BioSeeker Group AB Executive Summary Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. There are today more than 200 therapeutics targeting lymphoma in active development, from early preclinical to marketed drugs. \| more...	1/20/2009	$2,099.00
Angiogenesis in Oncology: Drug Pipeline Update 2009 By: BioSeeker Group AB Executive Summary There are today at least 250 anti-angiogenic/vascular disruptive/vascular targeting agents drugs in active development for the treatment of various cancers, from early preclinical to marketed drugs. In addition, the accumulated number of \| more...	1/20/2009	$2,099.00
Target Atlas in Oncology Drug Development: Targeted Therapies By: BioSeeker Group AB With the emergence of new technologies and an increased understanding of the biological basis for cancer evolution, the molecular changes that distinguish malignant-cells from normal cells are becoming increasingly apparent, offering a growing range of \| more...	1/1/2009	$8,050.00
Triple Target Atlas in Oncology Drug Development By: BioSeeker Group AB With the emergence of new technologies and an increased understanding of the biological basis for cancer evolution, the molecular changes that distinguish malignant-cells from normal cells are becoming increasingly apparent, offering a growing range of \| more...	1/1/2009	$4,830.00
Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy By: BioSeeker Group AB With the emergence of new technologies and an increased understanding of the biological basis for cancer evolution, the molecular changes that distinguish malignant-cells from normal cells are becoming increasingly apparent, offering a growing range of \| more...	1/1/2009	$11,130.00
Target Atlas in Oncology Drug Development: Major Tumor Types By: BioSeeker Group AB With the emergence of new technologies and an increased understanding of the biological basis for cancer evolution, the molecular changes that distinguish malignant-cells from normal cells are becoming increasingly apparent, offering a growing range of \| more...	1/1/2009	$6,440.00
Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis By: BioSeeker Group AB Not surprisingly, an increasing number of companies have turned their attention to the cancer targeted therapy market, undoubtedly trying to emulate the blockbuster status that several brands have already achieved. This report aims \| more...	12/19/2008	$2,730.00
Currently Druggable in Melanoma:A Drug Target Competitive Analysis By: BioSeeker Group AB This report aims to analyze the current and future potential of melanoma pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape \| more...	10/14/2008	$2,730.00
Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis By: BioSeeker Group AB This report aims to analyze the current and future potential of prostate cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive \| more...	9/8/2008	$3,100.00
Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis By: BioSeeker Group AB This report aims to analyze the current and future potential of breast cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive \| more...	8/12/2008	$3,100.00
Cancer Antibodies: Competitive Positioning for Success By: BioSeeker Group AB Executive Summary This report aims to analyze the current and future potential of cancer antibodies by examining key fundamentals across the entire pipeline of antibody drug candidates. BioSeeker has identified three fundamental dimensions to outline the \| more...	6/3/2008	$3,100.00
Cancer Vaccines: Aim and Shoot By: BioSeeker Group AB Executive Summary This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates. BioSeeker has identified three fundamental dimensions to outline \| more...	5/19/2008	$3,100.00
Leukemia Drug Pipeline Update 2009 By: BioSeeker Group AB Executive Summary Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. There are today more than 240 therapeutics targeting leukemia in active development, from early preclinical to marketed \| more...	4/20/2008	$2,099.00
Hematological Cancers Drug Pipeline Update 2009 By: BioSeeker Group AB Executive Summary Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity. There are today more than 360 therapeutics targeting hematological cancers in active \| more...	4/20/2008	$2,799.00
Deployment of Antibody Technologies in Oncology By: BioSeeker Group AB The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Targeted biologics utilizing monoclonal antibody (mAb)-based technologies have rapidly developed into one of the major \| more...	4/1/2008	$2,990.00
The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics By: BioSeeker Group AB The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Targeted biologics utilizing monoclonal antibody (mAb)-based technologies have rapidly developed into one of the major \| more...	4/1/2008	$3,575.00
Nordic Life Science Industry Guide 2008 By: BioSeeker Group AB The "Nordic Life Science Industry Guide 2008" is a unique CD-ROM product that contains a searchable directory of 1,500 life science companies in Scandinavia (Denmark, Norway, Finland and Sweden). BioSeeker has divided the industry into \| more...	3/18/2008	$299.00
Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology By: BioSeeker Group AB There is a plethora of new anti-angiogenic drugs in development. The potential to block tumor growth and metastases by angiogenesis inhibition represents an intriguing therapeutic strategy for the treatment of cancer and never before have \| more...	3/17/2008	$3,850.00
The Drug Target Atlas of Apoptopic Drugs in Oncology By: BioSeeker Group AB Executive Summary The ultimate goal of cancer research is to learn how to make cancer cells selectively die. Apoptosis is the type of death about whose genetically controlled pathways we know the most. Apoptotic cell death can \| more...	2/6/2008	$3,675.00
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer By: BioSeeker Group AB This is the report for professionals interested to grasp the field of apoptopic drug targets in oncology and at the same time have an extensive R&D overview of breast- and prostate cancer. This extensive 450+ \| more...	2/6/2008	$5,175.00
Title	Published	Price

< prev 1 2 3 4 5 6 7 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/21/2009 - 3